Abstract:AbstractType VI CRISPR enzymes have recently been identified as programmable RNA-guided, RNA-targeting Cas proteins with nuclease activity that allow for specific and robust target gene knock-down without altering the genome. However, we currently lack information about optimal Cas13 guide RNA designs for high target RNA knock-down efficacy. To close this gap, we conducted four massively-parallel Cas13 screens targeting the mRNA of a destabilized green fluorescent protein (GFP)… Show more
“…Optimization of gRNA design may further improve these systems as CasRx gRNAs have been shown to have variable knockdown efficiency. 5,53 Nevertheless, this is an important first step towards making transcriptome engineering a viable in vivo technology and provides a foundation for future experiments to mitigate the off-target and toxic attributes of the enzyme to make a new, viable tool in the expanding gene-editing toolbox.…”
CRISPR-Cas genome editing technologies have revolutionized the fields of functional genetics and genome engineering, but with the recent discovery and optimization of RNA-targeting Cas ribonucleases, we may soon see a similar revolution in the study of RNA function and transcriptome engineering. However, to date, successful proof of principle for Cas ribonuclease RNA targeting in eukaryotic systems has been limited. Only recently has successful modification of RNA expression by a Cas ribonuclease been demonstrated in animal embryos. This previous work, however, did not evaluate endogenous expression of Cas ribonucleases and only focused on function in early developmental stages. A more comprehensive evaluation of this technology is needed to assess its potential impact. Here we report on our efforts to develop a programmable platform for RNA targeting using a Cas ribonuclease, CasRx, in the model organism Drosophila melanogaster. By genetically encoding CasRx in flies, we demonstrate moderate transcript targeting of known phenotypic genes in addition to unexpected toxicity and lethality. We also report on the off-target effects following on-target transcript cleavage by CasRx. Taken together, our results present the current state and limitations of a genetically encoded programmable RNA-targeting Cas system in Drosophila melanogaster, paving the way for future optimization of the system.
“…Optimization of gRNA design may further improve these systems as CasRx gRNAs have been shown to have variable knockdown efficiency. 5,53 Nevertheless, this is an important first step towards making transcriptome engineering a viable in vivo technology and provides a foundation for future experiments to mitigate the off-target and toxic attributes of the enzyme to make a new, viable tool in the expanding gene-editing toolbox.…”
CRISPR-Cas genome editing technologies have revolutionized the fields of functional genetics and genome engineering, but with the recent discovery and optimization of RNA-targeting Cas ribonucleases, we may soon see a similar revolution in the study of RNA function and transcriptome engineering. However, to date, successful proof of principle for Cas ribonuclease RNA targeting in eukaryotic systems has been limited. Only recently has successful modification of RNA expression by a Cas ribonuclease been demonstrated in animal embryos. This previous work, however, did not evaluate endogenous expression of Cas ribonucleases and only focused on function in early developmental stages. A more comprehensive evaluation of this technology is needed to assess its potential impact. Here we report on our efforts to develop a programmable platform for RNA targeting using a Cas ribonuclease, CasRx, in the model organism Drosophila melanogaster. By genetically encoding CasRx in flies, we demonstrate moderate transcript targeting of known phenotypic genes in addition to unexpected toxicity and lethality. We also report on the off-target effects following on-target transcript cleavage by CasRx. Taken together, our results present the current state and limitations of a genetically encoded programmable RNA-targeting Cas system in Drosophila melanogaster, paving the way for future optimization of the system.
“…For example, the phenotypes of y varied by their expression, with ubiquitous expression of CasRx resulting in a Ubiq-CasRx/+; gRNA y /+ lethal phenotype and embryo and wing and body specific expression mitigated lethality phenotype seen in Ubiq-CasRx expression. Optimization of gRNA design may further improve these systems as CasRx gRNAs have been shown to have variable knockdown efficiency [5,47]. Nevertheless, this is an important first step towards making transcriptome engineering a viable in vivo technology and provides a foundation for future experiments to mitigate the off-target and toxic attributes of the enzyme to make a new, viable tool in the expanding gene-editing toolbox.…”
CRISPR-Cas genome editing technologies have revolutionized the fields of functional genetics and genome engineering, but with the recent discovery and optimization of RNA-targeting Cas ribonucleases, we may soon see a similar revolution in the study of RNA function and transcriptome engineering. However, to date, successful proof-of-principle for Cas ribonuclease RNA targeting in eukaryotic systems has been limited. Only recently has successful modification of RNA expression by a Cas ribonuclease been demonstrated in animal embryos. This previous work, however, did not evaluate endogenous expression of Cas ribonucleases and only focused on Cas ribonuclease function in early developmental stages. A more comprehensive evaluation of this technology is needed to assess its potential impact in the field. Here we report on our efforts to develop a programmable platform for RNA-targeting using a Cas ribonuclease, CasRx, in the model organism Drosophila melanogaster. By genetically encoding CasRx in flies, we demonstrate moderate transcript targeting of known phenotypic genes in addition to unexpected toxicity and lethality. We also report on the off-target effects following on-target transcript cleavage by CasRx. Taken together, our results present the current state and limitations of a genetically encoded programmable RNA-targeting Cas system in Drosophila melanogaster, paving the way for future optimization of the system.
“…The limitation of the one-vector system was also recently noted in an independent study 44 . To overcome this issue, we used two separate lentiviral vectors for dCas13d and gRNA expression, which were sequentially transduced into cells, similar to recent Cas13d-based knockdown screens published during the course of this study [42][43][44][45][46][47][48] . Another key issue that made dCas13d-based screening more challenging, compared to Cas13d-based knockdown screening, is likely the requirement for more stable binding of dCas13d/gRNA and target sites to effectively compete with cognate RNA-binding effectors.…”
Section: Discussionmentioning
confidence: 99%
“…Several studies indicated that gRNA length may affect the efficiency of Cas13d-mediated target RNA cleavage 42,45,47,56 . In our initial transfections, we used the 22-nt gRNA D [9,30] targeting the ISS-N1 region as a positive control segRNA.…”
Section: Specific Splicing Activation and Repression Through Transien...mentioning
confidence: 99%
“…Targeted cleavage of specific RNA transcripts by the Cas13 protein is achieved by using a guide RNA (gRNA) that consists of a direct repeat (DR) and a 22-30 nucleotide (nt) spacer that is complementary to the target RNA sequence. The Cas13 system has been used to perform high-throughput knockdown screenings of genes that influence cellular fitness, including by targeting circular RNAs and long noncoding RNAs [42][43][44][45][46][47][48] , through the use of a pooled lentiviral gRNA library. In addition, the catalytically dead Cas13 (dCas13) has been used as a programmable RNA-binding module, fused to various effector domains for applications in RNA editing 49 , m 6 A modifications 50 , modulation of splicing 37,51,52 and polyadenylation 53 , live cell RNA imaging 54 , and mapping of protein-RNA interactions through proximity ligation 55 .…”
Pre-mRNA splicing, a key process in gene expression, can be therapeutically modulated using various drug modalities, including antisense oligonucleotides (ASOs). However, determining promising targets is impeded by the challenge of systematically mapping splicing-regulatory elements (SREs) in their native sequence context. Here, we use the catalytically dead CRISPR-RfxCas13d RNA-targeting system (dCas13d/gRNA) as a programmable platform to bind SREs and modulate splicing by competing against endogenous splicing factors. SpliceRUSH, a high-throughput screening method, was developed to map SREs in any gene of interest using a lentivirus gRNA library that tiles the genetic region, including distal intronic sequences. When applied toSMN2, a therapeutic target for spinal muscular atrophy, SpliceRUSH robustly identified not only known SREs, but also a novel distal intronic splicing enhancer, which can be targeted to alter exon 7 splicing using either dCas13d/gRNA or ASOs. This technology enables a deeper understanding of splicing regulation with applications for RNA-based drug discovery.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.